Evidence map›Paper›PMID 25639451›Full record

ArticleClinical and experimental immunology2015

Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection.

Q Zheng, Y Y Zhu, J Chen, Y B Ye, J Y Li, Y R Liu, M L Hu, Y C Zheng, J J Jiang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Innate immunity and early liver inflammation.Frontiers in immunology · 2023
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Natural killer cells in liver diseases.Frontiers of medicine · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Q ZhengCenter for Liver Disease, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Y Y ZhuCenter for Liver Disease, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
J ChenCenter for Liver Disease, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Y B YeLab of Immunooncology, Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, China.
J Y LiLab of Immunooncology, Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, China.
Y R LiuCenter for Liver Disease, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
M L HuDepartment of Gastroenterology, Jinhua Central Hospital, Zhejiang, China.
Y C ZhengCenter for Liver Disease, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
J J JiangCenter for Liver Disease, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
First Affiliated Hospital of Fujian Medical University · CNFujian Medical University · CNFujian Provincial Cancer Hospital · CNJinhua Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence indicates that natural killer (NK) cells may contribute to liver injury in patients with hepatitis B virus (HBV) infection. Because HBV infection progresses through various disease phases, the cytolytic profiles of peripheral and intrahepatic NK cells in HBV-infected patients remain to be defined. In this study, we comprehensively characterized intrahepatic and peripheral NK cells in a cohort of HBV-infected individuals, and investigated their impact on liver pathogenesis during chronic HBV infection. The study population included 34 immune-clearance (IC) patients, 36 immune-tolerant (IT) carriers and 10 healthy subjects. We found that the activity of peripheral NK cells from IC patients was functionally elevated compared to IT carriers and controls, and NK cell activation was indicated by an increased expression of CD69, CD107a, interferon (IFN)-γ and tumour necrosis factor (TNF)-α. Further analysis showed that the increased activity of both peripheral and hepatic NK cells was correlated positively with liver injury, which was assessed by serum alanine aminotransferase levels (ALT) and the liver histological activity index (HAI). Interestingly, the frequency of peripheral NK cells was reduced in IC patients (especially those with higher HAI scores of 3-4), but there was a concomitant increase in hepatic NK cells. The functionally activated NK cells are enriched preferentially in the livers of IC patients and skew towards cytolytic activity that accelerates liver injury in chronic hepatitis B (CHB) patients.

Indexed as

AdolescentAdultBiopsyCell DegranulationCytokinesFemaleHepatitis B, ChronicHepatitis B virusHumansImmunohistochemistryKiller Cells, NaturalLiverLiver Function TestsLymphocyte ActivationMaleMiddle AgedCytokineschronic hepatitis Bcytokineinnate immunityliver injurynatural killer cells

Identifiers

PMID25639451
PMCPMC4449778
OpenAlexW1902888621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.